Genetic predisposition to cancer in man

Lips, K.; Veer, J. van der Sluys; Struyvenberg, A; Geerdink, R. A.

doi:10.1016/0002-9343(82)90710-0

Cited by 21 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Uric acid is metabolized by the liver, and it has been suggested that progressive liver damage may result in decreased serum uric acid production[ 11 ]. In addition, it has been suggested that cirrhotic patients have higher uric acid clearance than non-cirrhotic patients[ 41 ]. All the pathophysiological mechanisms support our finding.…”

Section: Discussionmentioning

confidence: 99%

Association of hyperuricemia with disease severity in chronic hepatitis C patients

et al. 2018

View full text Add to dashboard Cite

Background/aimsHepatitis C virus (HCV) infection is associated with extrahepatic manifestations such as metabolic abnormalities. The association between chronic hepatitis C (CHC) and uric acid levels has rarely been investigated. We aimed to evaluate the levels of serum uric acid in CHC patients.MethodsThree hundred and seventy-three histologically confirmed CHC patients who were scheduled to receive antiviral therapy were consecutively enrolled, and 746 age- and sex-matched uninfected controls were included for comparison. Hyperuricemia was defined as a uric acid level > 7 mg/dL in men and > 6.0 mg/dL in women.ResultsHyperuricemia was identified in 15.8% of the CHC patients. The uric acid levels did not differ between the CHC patients and the controls (5.54 ± 1.20 mg/dL vs. 5.45 ± 1.45 mg/dL, P = 0.3). Among the 373 CHC patients, the factors associated with hyperuricemia included body mass index (BMI) (OR/CI: 1.13/1.04–1.21, P = 0.003) and estimated glomerular filtration rate (eGFR) (OR/CI: 0.98/0.97–1.00, P = 0.02). Logistic regression analysis revealed that the factors associated with hyperuricemia in male patients included BMI (OR/CI: 1.12/1.05–1.30, P = 0.006) and advanced fibrosis (F3-4) (OR/CI: 0.27/0.09–0.83, P = 0.02), whereas the factors associated with hyperuricemia in female patients included eGFR (OR/CI: 0.97/0.95–0.99, P = 0.02) and diabetes (OR/CI: 3.03/1.11–8.25, P = 0.03). There was a significant decreasing trend of serum uric acid levels with the progression of fibrotic stages among male patients (6.21 ± 1.03 mg/dL 5.82 ± 1.16 mg/dL and 5.44 ± 1.28 mg/dL in stages F0-2, F3, and F4, respectively, trend P = 0.01).ConclusionsHyperuricemia was inversely associated with liver disease severity in CHC male patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of hyperuricemia with disease severity in chronic hepatitis C patients

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The primary RNA transcript for the CALC I gene is differentially processed in a cell-specific manner to include exon 4 in the thyroidal C-cells and exclude this exon in neuronal cells. However, mRNAs containing the CALC II exon 4 have never been observed in tissues or cell lines expressing this gene (5,6). The CALC Ill gene lacks an exon 4 region.…”

Section: Introductionmentioning

confidence: 99%

“…The CALC Ill gene lacks an exon 4 region. Therefore, while all three of these genes maintain the capacity to produce CGRP, only the CALC I gene is capable of CT production (5).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of exon sequences and an exon binding protein involved in alternative RNA splicing of calcitonin/CGRP

Cote¹,

Stolow²,

Peleg³

et al. 1992

Nucl Acids Res

View full text Add to dashboard Cite

Transcripts derived from the 6 exon CALC I gene are differentially processed in a tissue-specific fashion to include or exclude a calcitonin-specific exon 4. All cell types which transcribe a second calcitonin/CGRP gene, CALC II, exclude exon 4. Substitution of the first 30 nucleotides of CALC I exon 4 with analogous CALC II sequence was sufficient to prevent recognition of exon 4 in in vitro or in vivo RNA splicing systems. UV crosslinking detected a approximately 66 kDa RNA-binding protein in HeLa nuclear extract which interacted with CALC I proximal exon sequence, but not CALC II or mutant sequences. UV crosslinking of this protein was inhibited by addition of nuclear extract from a cell type which normally causes exclusion of exon 4. These results identify an important regulatory element within exon 4 and support a model in which calcitonin production requires protein interaction with this sequence to facilitate exon recognition.

show abstract

“…Second, these registries reflect the long term effects of preventive programs (e.g., stopping smoking), the application of diagnostic procedures (e.g., screening for uterine or breast cancer) or therapies (survival curves). A special type of tumor registry has been started in the Netherlands to make possible the screening of genetically conditioned neoplasms, one of which is the multiple endocrine neoplasms syndrome 2A, Sipple's syndrome (19).…”

Section: Registriesmentioning

confidence: 99%

Data Bases for the Assessment of Medical Technologies: Examples from Europe

Gutzwiller

Chrzanowski

Paccaud

1988

Int J Technol Assess Health Care

View full text Add to dashboard Cite

The assessment of medical technologies has to answer several questions ranging from safety and effectiveness to complex economical, social, and health policy issues. The type of data needed to carry out such evaluation depends on the specific questions to be answered, as well as on the stage of development of a technology. Basically two types of data may be distinguished: (a) general demographic, administrative, or financial data which has been collected not specifically for technology assessment; (b) the data collected with respect either to a specific technology or to a disease or medical problem. On the basis of a pilot inquiry in Europe and bibliographic research, the following categories of type (b) data bases have been identified: registries, clinical data bases, banks of factual and bibliographic knowledge, and expert systems. Examples of each category are discussed briefly. The following aims for further research and practical goals are proposed: criteria for the minimal data set required, improvement to the registries and clinical data banks, and development of an international clearinghouse to enhance information diffusion on both existing data bases and available reports on medical technology assessments.

show abstract

Genetic predisposition to cancer in man

Cited by 21 publications

References 3 publications

Association of hyperuricemia with disease severity in chronic hepatitis C patients

Association of hyperuricemia with disease severity in chronic hepatitis C patients

Identification of exon sequences and an exon binding protein involved in alternative RNA splicing of calcitonin/CGRP

Data Bases for the Assessment of Medical Technologies: Examples from Europe

Contact Info

Product

Resources

About